T
Thomas Büchner
Researcher at University of Münster
Publications - 157
Citations - 19364
Thomas Büchner is an academic researcher from University of Münster. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 52, co-authored 157 publications receiving 16741 citations.
Papers
More filters
Journal ArticleDOI
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner,Elihu H. Estey,David Grimwade,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Richard A. Larson,Ross L. Levine,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Hwei-Fang Tien,Andrew H. Wei,Andrew H. Wei,Bob Löwenberg,Clara D. Bloomfield +22 more
TL;DR: An international panel to provide updated evidence- and expert opinion-based recommendations for diagnosis and management of acute myeloid leukemia in adults includes a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
Journal ArticleDOI
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Döhner,Elihu H. Estey,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Alan Kenneth Burnett,Hervé Dombret,Pierre Fenaux,David Grimwade,Richard A. Larson,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Bob Löwenberg,Clara D. Bloomfield +18 more
TL;DR: An international expert panel is provided to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials.
Journal ArticleDOI
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson,John M. Bennett,Kenneth J. Kopecky,Thomas Büchner,Cheryl L. Willman,Elihu H. Estey,Charles A. Schiffer,Hartmut Doehner,Martin S. Tallman,T. Andrew Lister,Francesco Lo-Coco,Roel Willemze,Andrea Biondi,Wolfgang Hiddemann,Richard A. Larson,Bob Löwenberg,Miguel A. Sanz,David R. Head,Ryuzo Ohno,Clara D. Bloomfield +19 more
TL;DR: An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials as mentioned in this paper.
Journal ArticleDOI
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Miguel A. Sanz,David Grimwade,Martin S. Tallman,Bob Löwenberg,Pierre Fenaux,Elihu H. Estey,Tomoki Naoe,Eva Lengfelder,Thomas Büchner,Hartmut Döhner,Alan Kenneth Burnett,Francesco Lo-Coco +11 more
TL;DR: This review contains specific recommendations for the identification and management of most important complications such as the bleeding disorder, APL differentiation syndrome, QT prolongation and other ATRA- and ATO-related toxicities, as well as for molecular assessment of response to treatment.
Journal ArticleDOI
A 17-gene stemness score for rapid determination of risk in acute leukaemia
Stanley W.K. Ng,Amanda Mitchell,James A. Kennedy,James A. Kennedy,James A. Kennedy,Weihsu C. Chen,Jessica McLeod,Narmin Ibrahimova,Andrea Arruda,Andreea C. Popescu,Vikas Gupta,Vikas Gupta,Vikas Gupta,Aaron D. Schimmer,Andre C. Schuh,Andre C. Schuh,Andre C. Schuh,Karen W.L. Yee,Karen W.L. Yee,Karen W.L. Yee,Lars Bullinger,Tobias Herold,Tobias Herold,Dennis Görlich,Thomas Büchner,Wolfgang Hiddemann,Wolfgang Hiddemann,Wolfgang E. Berdel,Bernhard Wörmann,Meyling Cheok,Claude Preudhomme,Hervé Dombret,Klaus H. Metzeler,Klaus H. Metzeler,Christian Buske,Bob Löwenberg,Peter J. M. Valk,Peter W. Zandstra,Mark D. Minden,John E. Dick,John E. Dick,Jean C.Y. Wang,Jean C.Y. Wang,Jean C.Y. Wang +43 more
TL;DR: The LSC17 score provides clinicians with a rapid and powerful tool to identify AML patients who do not benefit from standard therapy and who should be enrolled in trials evaluating novel upfront or post-remission strategies.